Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma.
Humans
YAP-Signaling Proteins
/ metabolism
Astrocytoma
/ metabolism
Adaptor Proteins, Signal Transducing
/ metabolism
Female
Male
Transcription Factors
/ genetics
Brain Neoplasms
/ metabolism
Middle Aged
Adult
Neoplasm Grading
Oligodendroglioma
/ genetics
Phosphoproteins
/ metabolism
Aged
Prognosis
Gene Expression Regulation, Neoplastic
Biomarkers, Tumor
/ metabolism
Transcriptional Coactivator with PDZ-Binding Motif Proteins
Trans-Activators
/ genetics
Young Adult
TAZ
YAP1
astrocytoma
low grade glioma
oligodendroglioma
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
28
02
2024
revised:
19
03
2024
accepted:
20
03
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
26
6
2024
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is one of the most lethal types of brain cancer with a median survival of only 12 months due to its aggressiveness and lack of effective treatment options. Astrocytomas and oligodendrogliomas are classified as low-grade gliomas (LGG) and have the potential to progress into secondary GBM. YAP1 and TAZ are transcriptional co-activators of the hippo pathway and play an important role in tumorigenesis by controlling cell proliferation and differentiation. The aim of this study was to analyze whether YAP1 and TAZ influence the survival in patients with astrocytoma and oligodendroglioma. A total of 22 patient samples of astrocytoma and 11 samples of oligodendroglioma were analyzed using real-time PCR. We utilized open-access data from The Cancer Genome Atlas (TCGA) focusing on "brain lower grade glioma". mRNA expression rates were used to validate our findings on survival analysis. Expression of YAP1 was twice as high in astrocytoma than in oligodendroglioma, whereas there was no difference in TAZ. In oligodendrogliomas, the expression of TAZ was higher in relapsed than in primary tumors. Patients with astrocytoma having a high YAP1 expression had a significantly shorter overall survival than patients with lower expression (median survival 161 vs. 86 months, p=0.0248). These findings were validated with survival analysis of TCGA data. High YAP1 expression shows a high correlation with poorer overall survival in LGG. YAP1 has higher levels of expression in astrocytomas than in oligodendrogliomas.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Glioblastoma multiforme (GBM) is one of the most lethal types of brain cancer with a median survival of only 12 months due to its aggressiveness and lack of effective treatment options. Astrocytomas and oligodendrogliomas are classified as low-grade gliomas (LGG) and have the potential to progress into secondary GBM. YAP1 and TAZ are transcriptional co-activators of the hippo pathway and play an important role in tumorigenesis by controlling cell proliferation and differentiation. The aim of this study was to analyze whether YAP1 and TAZ influence the survival in patients with astrocytoma and oligodendroglioma.
PATIENTS AND METHODS
METHODS
A total of 22 patient samples of astrocytoma and 11 samples of oligodendroglioma were analyzed using real-time PCR. We utilized open-access data from The Cancer Genome Atlas (TCGA) focusing on "brain lower grade glioma". mRNA expression rates were used to validate our findings on survival analysis.
RESULTS
RESULTS
Expression of YAP1 was twice as high in astrocytoma than in oligodendroglioma, whereas there was no difference in TAZ. In oligodendrogliomas, the expression of TAZ was higher in relapsed than in primary tumors. Patients with astrocytoma having a high YAP1 expression had a significantly shorter overall survival than patients with lower expression (median survival 161 vs. 86 months, p=0.0248). These findings were validated with survival analysis of TCGA data.
CONCLUSION
CONCLUSIONS
High YAP1 expression shows a high correlation with poorer overall survival in LGG. YAP1 has higher levels of expression in astrocytomas than in oligodendrogliomas.
Identifiants
pubmed: 38925840
pii: 44/7/3005
doi: 10.21873/anticanres.17113
doi:
Substances chimiques
YAP-Signaling Proteins
0
YAP1 protein, human
0
Adaptor Proteins, Signal Transducing
0
Transcription Factors
0
Phosphoproteins
0
WWTR1 protein, human
0
Biomarkers, Tumor
0
Transcriptional Coactivator with PDZ-Binding Motif Proteins
0
Trans-Activators
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3005-3011Informations de copyright
Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.